

Name of the Issue: Eris Lifesciences Limited

1 Type of Issue IPO

2 Issue Size (Rs. Cr) 1,741.16

Source: Prospectus dated June 21, 2017

3 Grade of issue along with name of the rating agency

Name Not applicable

Grade Not applicable

4 Subscription Level (Number of times) 3.29

Notes:

¹⁾ The above figures are before technical rejections

Source: Final Post Issue Report

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to Stock Exchanges

Particulars	Number of Shares	%age
(i) On Allotment ⁽¹⁾		17.41%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2017)		17.39%
(iii) at the end of 1st FY (March 31, 2018)		19.41%
(iv) at the end of 2nd FY (March 31, 2019)		19.79%
(v) at the end of 3rd FY (March 31, 2020)		21.37%

Source:

⁽¹⁾ Basis of Allotment

6 Financials of the issuer

(Rs. Crore)

Parameters	1st FY (FY 2018)	2nd FY (FY 2019)	3rd FY (FY 2020)
Net Sales/ Income from operations	855.6	982.2	1074.1
Net Profit	294.1	290.8	295.3
Paid up Equity Share Capital	13.8	13.8	13.6
Reserves excluding revaluation reserves	847.6	1136.8	1282.8

7 Trading Status

Particulars	BSE	NSE
(i) at the end of 1st FY (FY 2018)	Infrequently Traded	Frequently Traded
(ii) at the end of 2nd FY (FY 2019)	Infrequently Traded	Infrequently Traded
(iii) at the end of 3rd FY (FY 2020)	Infrequently Traded	Frequently Traded

8 Change in Directors

Particulars	Name of Director	Appointed / Resigned
During year ended March 31, 2018	Shardul Suresh Shroff	Resigned
	Rajiv Gulati	Resigned
During year ended March 31, 2019	Prashant Gupta	Appointed
During year ended March 31, 2020	Cherian Mathew	Appointed

9 Status of implementation of project/ commencement of commercial production

(i) Details of Estimated Schedule of Implementation of Projects forming part of Objects of the Issue	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	Not Applicable
(ii) Actual utilization	Not Applicable
(iii) Reasons for deviation, if any	Not Applicable

11 Comments of monitoring agency, if applicable Not applicable

- (a) Comments on use of funds
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document
(c) Any other reservations expressed by the monitoring agency about the end use of funds

12 Pricing Data

Issue Price (Rs.) Rs. 603

Price parameters	At close of listing day i.e. June 29, 2017	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of FY 2018			As at the end of FY 2019			As at the end of FY 2020		
				Closing price	High	Low	Closing price	High	Low	Closing price	High	Low
Market Price (NSE)	601.50	608.25	568.70	799.75	803.00	760.00	644.90	820.00	572.50	368.90	638.75	362.15
NSE Nifty	9,504.10	10,014.50	9,871.50	10,113.70	10,158.35	10,096.90	11,623.90	11,760.20	10,004.55	8,597.75	12,362.30	7,610.25
Sectoral Index	9428.2	9,672.60	9,297.90	8,358.05	8,456.70	8,332.15	9,346.55	10,786.35	7,900.35	7,176.50	9,461.70	6,432.30

NIFTY Pharma is the sectoral index for above disclosure

13 Basis for Issue Price

Accounting ratio	Name of Company	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (FY 2018)	At the end of 2nd FY (FY 2019)	At the end of 3rd FY (FY 2020)
EPS (Basic)(Rs.)	Issuer :	17.61	21.39	21.13	21.61
	Peer Group:				
	GlaxoSmithKline Pharmaceuticals Limited	39.80	41.41	26.29	5.50
	Abbott India Limited	130.19	188.81	211.93	279.04
	Sanofi India Limited	129.13	141.55	165.30	179.85
	Pfizer Limited	73.61	78.70	93.80	111.28
	Industry Avg:	93.18	112.62	124.33	143.92
P/E (Basic EPS)	Issuer:	34.24	37.39	30.45	17.05
	Peer Group:				
	GlaxoSmithKline Pharmaceuticals Limited	61.51	50.42	42.72	226.41
	Abbott India Limited	31.41	28.88	34.43	55.39
	Sanofi India Limited	31.65	33.49	38.44	39.01
	Pfizer Limited	23.48	27.77	35.41	36.17
	Industry Avg:	37.01	35.14	37.75	89.26
RoNW (%)	Issuer:	44.84	41.18	28.91	89.25
	Peer Group:				
	GlaxoSmithKline Pharmaceuticals Limited	16.78	17.26	21.22	4.90
	Abbott India Limited	19.95	26.06	24.33	24.18
	Sanofi India Limited	17.11	16.68	17.93	16.28
	Pfizer Limited	13.92	14.11	15.07	14.73
	Industry Avg:	16.94	18.53	19.64	15.02
NAV per share	Issuer:	39.21	62.64	83.66	95.47
	Peer Group:				
	GlaxoSmithKline Pharmaceuticals Limited	236.93	242.90	126.47 ⁽²⁾	107.47
	Abbott India Limited	652.70	796.60	945.22	1144.37
	Sanofi India Limited	753.62	879.90	963.60	1060.46
	Pfizer Limited	528.74	586.50	658.25	742.22
	Industry Avg:	543.00	626.48	855.69	763.63

Notes:

⁽¹⁾ Sourced from the Prospectus dated June 21, 2017

⁽²⁾ After Bonus issue of 1:1 on September 13, 2018, Adjusted for the said issue, the NAV per share is INR 252.94.

14 Any other material information

Particulars	Date
Eris Lifesciences acquired trademark 'Zomelis' and its associated trademarks from Novartis AG, based at Basel Switzerland for Indian pharmaceuticals market with effect from 10th December 2019, for USD 13mn	03-Dec-19
Buyback of shares through tender offer approved by the Board of Directors	03-Jul-19
Addition of the following clauses to the object clause of the Memorandum of Association of the Company:	
<i>"To carry on the business of manufacturing, trading, importing, exporting, supplying, innovating, researching, developing, improvising, allowing hired use, loaning equipment relating to fitness, wellness, fitness testing or measurement (whether electronic, electrical, mechanical or any combination thereof), healthcare, laboratory, patient need tools, implements, equipment, healthcare, recuperative or preventive intervention"</i>	29-Sep-18
<i>"To carry on the business of manufacturing, trading, importing, exporting, supplying, innovating, researching, developing Cosmetics, Cosmeceutical, beauty, appearance enhancement products, essences, personal hygiene or personal care products, health Care products, substances adapted for medical use, nutritional products, nutritional additives or supplements and any other like healthcare, wellness, recuperative or preventive intervention including without limitation dietary supplements, vitamins, minerals, fibre, fatty acids, amino acids, protein containing supplements, modified foods, dietetic substances, health foods and allied foods products, whether in ready to drink or eat form or otherwise."</i>	
Completion of execution of documents aimed at creating securities in favour of Axis Bank for part financing the acquisition of business undertaking of the domestic formulation business containing brands / trademarks / assets of M/s Strides Shasun Limited	27-Jun-18
Intimation of Long-Term Credit rating of CRISIL AA- with a Stable outlook on INR 400Cr of Bank Loan loan Facilities	01-Jun-18
Change in Internal Auditor - Dharmesh Parikh & Co. resigned due to other professional commitments. Mrs. Vidya Bhaskar Subramanian, AGM, Finance Department has been appointed as Internal Auditor	13-Feb-18
Company has entered into definitive agreements with Strides Shasun Limited for acquisition of 'India brand business' for cash consideration of INR 500 crores	18-Nov-17
Company has entered into a Share Purchase Agreement dated October 1, 2017 with UTH Healthcare and its shareholders for the acquisition of entire shareholding of UTH Healthcare	01-Oct-17
Board of Directors of the Company at their meeting held today i.e. August 17, 2017 has also transacted the following business:	
1. Approved the shifting of the Registered Office of the Company from 21, New York Tower - A, Nr. Muktidham Temple Thaltej Cross Road, Thaltej Ahmedabad- 380054 to 8th Floor, Commerce House IV, Beside Shell Petrol Pump, 100 Feet Road, Prahladnagar, Ahmedabad - 380015 with immediate effect.	17-Aug-17
2. Decided to convene the Eleventh Annual General Meeting (AGM) of the Members of the Company on Friday, September 29, 2017.	
The Corporate Identity Number (CIN) of the Company stands updated from 'U24232GJ2007PLC049867' to 'L24232GJ2007PLC049867' as a result of our listing intimation to the Registrar of Companies	18-Jul-17
<i>Source - Website of stock exchanges</i>	

DISCLAIMER:

The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the "Circular") for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance.

The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited (www.bseindia.com), The National Stock Exchange of India Limited (www.nseindia.com), websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as "www.capitalmarkets.com" and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise.

The information disclosed on this website is updated as of December 21, 2020. Citi does not undertake to update the information contained herein except as required by applicable law or regulation.